PR Newswire Clinical TrialsOriginal article
Cumulus Neuroscience présente, lors du congrès annuel de l'AAIC 2026, des données montrant qu'une tâche numérique de deux minutes atteint ou dépasse les critères de référence cliniques en matière de pré-sélection des participants à un essai clinique sur la maladie d'Alzheimer.
ConferencepositiveSymbol SwapNeuLogiqPositive
AI Analysis
Summary
Cumulus Neuroscience presented data at AAIC 2026 demonstrating that a two-minute digital task called Symbol Swap on the NeuLogiq platform met clinical benchmarks for screening Alzheimer's disease trial participants, showing significant distinction between control, MCI, and diseased populations across three independent studies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Two-minute digital task (Symbol Swap) demonstrated clinical significance in distinguishing between control groups, mild cognitive impairment (MCI) patients, and Alzheimer's disease patients across three independent studies
Importance:5/10
Sentiment:
0.65
neuroscienceAlzheimer's diseasedigital healthpatient screeningcognitive assessmentAAIC 2026
Read the original article
Published by PR Newswire Clinical Trials on July 15, 2026 1:54 PM